Research goal

Hair Loss & Regrowth

Q: Which peptides are researched for hair loss?

The most studied peptides in the context of hair loss and regrowth are GHK-Cu (copper tripeptide), TB-500 (Thymosin Beta-4 fragment), and BPC-157. GHK-Cu has the strongest direct evidence, with research showing it stimulates hair follicle proliferation, increases follicle size, and reverses miniaturisation in cell and tissue models. TB-500 promotes angiogenesis and cell migration, which may support follicle activation via improved scalp microcirculation. BPC-157 addresses scalp inflammation and vascular support through its angiogenic and anti-inflammatory mechanisms. Epitalon has also been examined in longevity and cellular renewal contexts, though hair-specific evidence is weaker. None of these compounds are FDA-approved for hair loss.

Q: Does GHK-Cu regrow hair?

GHK-Cu has demonstrated hair follicle stimulating effects in preclinical research, including studies showing increased hair follicle size, reversal of follicle miniaturisation, and stimulation of follicle cell proliferation. One line of research reported hair growth stimulation of over 1000% compared to controls in specific follicle models. However, this is preclinical data: large-scale randomised controlled trials in humans with pattern baldness are limited. GHK-Cu is available in topical formulations as well as subcutaneous research preparations. It is not FDA-approved for hair regrowth. The mechanistic evidence is plausible and consistent, but translating follicle model results to clinical hair density outcomes in androgenetic alopecia requires more rigorous human trial data.

Q: Can TB-500 help with hair loss?

TB-500 (the active LKKTETQ fragment of Thymosin Beta-4) promotes angiogenesis, cell migration, and tissue repair, mechanisms that are relevant to hair follicle biology because follicle cycling depends on adequate scalp microcirculation and stem cell activation. Some research has investigated Thymosin Beta-4 in the context of hair follicle stem cell activation and the anagen (growth) phase of the hair cycle. However, direct human clinical trial data on TB-500 for hair loss is limited compared to its tissue repair and wound healing research base. It is not an established hair loss treatment. Any interest in TB-500 for hair purposes should be understood in the context of its angiogenic mechanism rather than hair-specific evidence.

Q: Are peptides FDA-approved for hair regrowth?

No. The only FDA-approved treatments for hair loss (specifically androgenetic alopecia) are minoxidil (topical, available over the counter) and finasteride (oral, prescription only for men). Minoxidil works primarily through vasodilation and potassium channel opening at the follicle. Finasteride inhibits 5-alpha reductase, reducing conversion of testosterone to dihydrotestosterone (DHT), which drives follicle miniaturisation. Peptides such as GHK-Cu, TB-500, and BPC-157 are not approved for hair loss. They are researched through angiogenic, anti-inflammatory, and follicle proliferation mechanisms that are mechanistically distinct from both minoxidil and finasteride, but have not completed the clinical trial pathway required for FDA approval.

Q: How do peptides differ from minoxidil for hair loss?

Minoxidil is a vasodilator that was originally developed as an antihypertensive. Its hair-promoting effects are attributed to direct follicle stimulation via potassium channel opening, prolongation of the anagen (growth) phase, and increased scalp blood flow. Peptides like GHK-Cu operate through gene expression modulation, activating tissue remodelling and collagen synthesis pathways, and have demonstrated follicle proliferation effects in research models that are mechanistically different from minoxidil. TB-500 and BPC-157 work primarily through angiogenic and anti-inflammatory pathways. None of these peptides have the clinical trial evidence base that minoxidil has accumulated over decades of use. They are not alternatives to minoxidil in any approved clinical sense, but they operate through different biological pathways and are being investigated as potential adjuncts.

Research overview of peptides investigated for hair loss and regrowth, covering angiogenic, follicle-proliferative, and anti-inflammatory mechanisms. Peptides for hair follicle health represent a growing area of research interest. No compound on this page is FDA-approved for hair loss or regrowth. Content is an educational research reference only.

Relevant Compounds

Compound	Class	Primary mechanism	Relevance to hair	Link
GHK-Cu	Copper tripeptide	Activates tissue remodelling genes; stimulates collagen and glycosaminoglycan synthesis; angiogenic; anti-inflammatory	Follicle proliferation, follicle size increase, miniaturisation reversal, scalp circulation	View profile →
AHK-Cu	Copper tripeptide (GHK-Cu analogue)	Dermal papilla cell proliferation; anti-apoptotic (caspase-3, PARP reduction); VEGF upregulation; extracellular matrix remodelling	Hair follicle stimulation, dermal papilla proliferation, anagen phase support, perifollicular angiogenesis	View profile →
TB-500	Thymosin Beta-4 fragment (LKKTETQ)	Angiogenesis promotion; actin sequestration enabling cell migration; VEGF upregulation; anti-inflammatory	Scalp microcirculation, follicle stem cell activation, anagen phase support	View profile →
BPC-157	Pentadecapeptide / cytoprotective	Angiogenesis via VEGFR2; nitric oxide pathway modulation; anti-inflammatory; tissue vascularisation	Scalp inflammation reduction, improved blood flow, indirect follicle support	View profile →
Epitalon	Tetrapeptide / pineal bioregulator	Telomerase activation; antioxidant effects; gene expression modulation; normalises pineal function	Cellular renewal research, longevity-adjacent; weaker direct hair evidence	View profile →

Research Context

Hair loss affects both men and women and involves multiple converging biological mechanisms. Androgenetic alopecia, the most common form, is driven by genetic sensitivity of follicles to dihydrotestosterone (DHT), which shortens the anagen (growth) phase and progressively miniaturises follicles until they cease producing visible hair. However, DHT sensitivity is not the only driver: reduced scalp microcirculation limits follicle oxygenation and nutrient delivery, chronic low-grade follicle inflammation accelerates miniaturisation independently of DHT, stem cell exhaustion in the follicle bulge impairs regenerative capacity, and oxidative stress damages follicle DNA and mitochondria. Peptide research in the hair loss context focuses primarily on the non-DHT mechanisms, particularly angiogenesis, follicle proliferation, and inflammation resolution, rather than competing with the DHT-blockade approach of finasteride.

GHK-Cu is the most directly researched peptide for hair follicle biology. This naturally occurring copper-binding tripeptide, whose plasma concentration declines with age, has been shown in research models to increase hair follicle size by approximately 35%, stimulate keratinocyte and follicle cell proliferation, and activate gene networks involved in tissue remodelling, including those regulating the Wnt/beta-catenin pathway that controls follicle cycling and stem cell activity. One laboratory study reported hair growth stimulation exceeding 1000% in a follicle model, a figure frequently cited in peptide hair loss discussions. The clinical translation of these findings remains limited: head-to-head human trials comparing GHK-Cu to approved treatments in patients with androgenetic alopecia are not yet available, and the compound is not approved by the FDA for any hair loss indication.

TB-500 and BPC-157 reach the hair loss research context primarily through their angiogenic and anti-inflammatory properties rather than through dedicated follicle studies. Adequate scalp microvascular density is necessary for follicle viability, and angiogenesis is mechanistically upstream of the vascularisation that sustains follicle cycling. Thymosin Beta-4 has been studied in the context of wound-induced hair follicle neogenesis in animal models, suggesting a role in follicle stem cell mobilisation. BPC-157 addresses the inflammatory microenvironment at the scalp level, relevant because perifollicular fibrosis and mast cell infiltration are features of androgenetic alopecia progression that may accelerate miniaturisation beyond DHT effects alone.

The Wnt/beta-catenin pathway deserves specific mention as an emerging focus in peptide hair research. Wnt signalling drives the transition of follicle stem cells from quiescence to anagen activation, and its impairment contributes to shortened growth cycles and eventual follicle dropout. GHK-Cu has been shown to upregulate Wnt pathway components in research contexts, which positions it as potentially relevant to the upstream biology of follicle regeneration rather than simply a downstream growth stimulant. This is mechanistically distinct from both minoxidil (which operates via potassium channel opening and vascular effects) and finasteride (which operates via 5-alpha reductase inhibition), and represents the most plausible rationale for peptide-based approaches to hair research.

Key Research Mechanisms

Angiogenesis & Scalp Microcirculation

Hair follicles are metabolically demanding structures that require sustained oxygen and nutrient delivery from the perifollicular vasculature. Reduced scalp microvascular density has been documented in androgenetic alopecia and correlates with the degree of follicle miniaturisation. GHK-Cu promotes angiogenesis through upregulation of vascular endothelial growth factor (VEGF) and related signalling pathways. TB-500 is a potent promoter of angiogenesis via VEGF upregulation and actin-mediated endothelial cell migration. BPC-157 promotes vascularisation through VEGFR2 activation and nitric oxide pathway modulation. All three compounds may support follicle viability through improved scalp blood supply, though this has not been directly tested in controlled clinical trials in hair loss patients.

Follicle Proliferation & Size

GHK-Cu is the primary peptide with direct follicle proliferation research. Studies have demonstrated increases in follicle size, stimulation of follicle cell division, and upregulation of genes involved in the anagen growth phase. The miniaturisation of follicles in androgenetic alopecia produces progressively finer and shorter hairs over successive cycles; research suggesting reversal of miniaturisation via GHK-Cu is mechanistically important, though the clinical magnitude of this effect in humans requires larger trial data to establish. GHK-Cu also activates laminin-1, a matrix protein critical for follicle basement membrane integrity and follicle anchoring.

Anti-inflammatory Effects on the Scalp

Perifollicular inflammation and fibrosis are increasingly recognised as contributors to androgenetic alopecia progression that are independent of the DHT pathway. Histological studies of balding scalp show mast cell infiltration and collagen deposition around miniaturising follicles. BPC-157 has well-established anti-inflammatory properties via suppression of inflammatory cytokines and modulation of the NO pathway. GHK-Cu has documented anti-inflammatory gene expression effects, downregulating TNF-alpha and IL-6 among other mediators. Reducing this inflammatory microenvironment may slow miniaturisation and support follicle retention beyond what DHT-blocking approaches alone achieve.

Wnt/Beta-Catenin Pathway & Stem Cell Activation

The Wnt/beta-catenin signalling pathway is the primary molecular switch governing hair follicle stem cell activation and the transition from follicle quiescence to the anagen growth phase. Impairment of Wnt signalling shortens growth cycles and limits follicle regenerative capacity. GHK-Cu has been shown to modulate Wnt pathway components in tissue research models. TB-500 has been investigated in wound-healing contexts where hair follicle neogenesis occurs through mechanisms that involve stem cell mobilisation. Research into peptides operating through Wnt/beta-catenin pathways represents an emerging area distinct from the vasodilation and DHT-inhibition approaches of established treatments, though clinical validation in human alopecia populations remains limited.

Compound Notes

GHK-Cu

GHK-Cu is a naturally occurring copper-binding tripeptide (glycine-histidine-lysine) complexed with copper(II). Its plasma concentration declines substantially with age, and research has investigated whether exogenous administration can restore youthful tissue remodelling activity. In hair follicle research, GHK-Cu has been shown to stimulate follicle proliferation, increase follicle size, and activate gene networks associated with the anagen phase. It also stimulates the synthesis of laminin, decorin, and collagen IV, components of the follicle extracellular matrix that support follicle structure and anchoring. GHK-Cu is available in topical cosmetic preparations and as a subcutaneous research peptide. Its evidence base for hair specifically is stronger than for TB-500 or BPC-157, but still lacks large-scale human RCT data comparing it to approved treatments.

AHK-Cu

AHK-Cu (L-Alanyl-L-Histidyl-L-Lysine copper complex, also Copper Tripeptide-3) is a synthetic copper-binding tripeptide and structural analogue of GHK-Cu, differing only in the N-terminal amino acid (alanine in AHK-Cu versus glycine in GHK-Cu). This single substitution increases copper-binding affinity and produces a more targeted activity profile centred on dermal papilla cell biology. The foundational Pyo et al. 2007 study at Seoul National University demonstrated significant increases in human hair follicle elongation in an ex vivo model, dermal papilla cell proliferation (p < 0.001), and reductions in apoptosis markers: caspase-3 activity by 42.7% and PARP cleavage by 77.5% (p < 0.05). AHK-Cu also stimulates VEGF expression, supporting perifollicular angiogenesis. Its dose-response profile shows an important inversion: research activity occurs at 10-12 to 10-9 molar concentrations, and excess concentration may reduce efficacy. AHK-Cu is available in topical scalp serums, typically at 0.001% to 0.01%, and is frequently combined with GHK-Cu in dual-peptide formulations targeting hair and scalp health. It is not FDA-approved for any indication.

TB-500

TB-500 is the synthetically produced LKKTETQ fragment of Thymosin Beta-4, an endogenous peptide with roles in actin regulation, cell migration, and angiogenesis. Its primary research applications are in wound healing, tendon repair, and tissue regeneration, where its angiogenic and cell-migration-promoting properties are most directly relevant. The connection to hair loss research arises from studies showing that Thymosin Beta-4 activates hair follicle stem cells and promotes anagen initiation in wound-healing contexts, and from the general principle that follicle viability depends on adequate vascularisation. TB-500 for hair regrowth has generated community interest but direct clinical trial data in hair loss populations is limited. Its use in hair contexts should be understood as extrapolation from its wound healing and angiogenic research base.

BPC-157

BPC-157 (Body Protective Compound 157) is a 15-amino acid synthetic peptide derived from a protective protein in gastric juice. Its research applications span gut mucosal healing, tendon and ligament repair, joint protection, and systemic anti-inflammatory effects. Its relevance to hair research is indirect: the angiogenic effects via VEGFR2 activation may support scalp microcirculation, and its anti-inflammatory properties may reduce the perifollicular inflammation that contributes to androgenetic alopecia progression. BPC-157 does not have dedicated hair follicle research of the depth that GHK-Cu does. Its inclusion in hair loss research discussions reflects the general principle that reducing scalp inflammation and improving vascular supply can support follicle retention, rather than a direct follicle-specific mechanism.

Epitalon

Epitalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) studied primarily for its telomerase-activating properties and its potential to normalise age-related decline in pineal gland function. Its relevance to hair loss is primarily through longevity and cellular renewal mechanisms rather than follicle-specific research: telomere shortening in follicle stem cells has been proposed as a contributor to age-related hair thinning, and compounds that activate telomerase may theoretically extend follicle stem cell replicative capacity. The evidence for Epitalon specifically in hair contexts is weaker than for GHK-Cu, TB-500, or BPC-157. It is included here for research completeness given its cellular renewal research base.

Regulatory Note

No peptide discussed on this page is FDA-approved for hair loss or regrowth. The only FDA-approved treatments for androgenetic alopecia are minoxidil (topical, OTC) and finasteride (oral, prescription for men). Peptides such as GHK-Cu, TB-500, and BPC-157 are researched as potential adjuncts through angiogenic, follicle-proliferative, and anti-inflammatory mechanisms, but have not completed the clinical trial pathway required for FDA approval in hair loss. This page is an educational research reference and does not constitute medical advice. Anyone considering peptides for hair loss should consult a qualified dermatologist or physician familiar with their individual health status.

Frequently Asked Questions

Which peptides are researched for hair loss?

The most studied peptides for hair loss and regrowth are GHK-Cu, TB-500, and BPC-157. GHK-Cu has the most direct follicle-specific research, showing follicle proliferation, size increase, and miniaturisation reversal in preclinical models. TB-500 promotes angiogenesis and may support scalp microcirculation and stem cell activation. BPC-157 addresses scalp inflammation and vascular support. Epitalon has some cellular renewal research relevance. None are FDA-approved for hair loss.

Does GHK-Cu regrow hair?

GHK-Cu has demonstrated follicle-stimulating effects in preclinical research, including increased follicle size, reversal of follicle miniaturisation, and stimulation of follicle cell proliferation. The mechanistic evidence is consistent and plausible. However, large-scale human randomised controlled trials in androgenetic alopecia populations comparing GHK-Cu to approved treatments are not yet available. GHK-Cu is not FDA-approved for hair regrowth, and clinical translation of preclinical follicle model findings requires further human study.

Can TB-500 help with hair loss?

TB-500 promotes angiogenesis and cell migration, which may support follicle viability through improved scalp microcirculation and stem cell activation. Research on Thymosin Beta-4 in wound-healing contexts has shown follicle stem cell activation effects. However, direct human clinical trial data on TB-500 specifically for hair loss is limited. It is not an established hair loss treatment. Interest in TB-500 for hair purposes should be understood in the context of its angiogenic mechanism and the indirect relevance to follicle biology, rather than hair-specific clinical evidence.

Are peptides FDA-approved for hair regrowth?

No. The only FDA-approved treatments for androgenetic alopecia are minoxidil and finasteride. No peptide currently holds FDA approval for any hair loss indication. Peptides researched in this area operate through angiogenic, follicle-proliferative, and anti-inflammatory mechanisms, which are mechanistically distinct from minoxidil and finasteride, but have not completed the clinical trial process required for approval.

How do peptides differ from minoxidil for hair loss?

Minoxidil works primarily through vasodilation, potassium channel opening, and direct follicle stimulation, extending the anagen phase. Finasteride inhibits 5-alpha reductase, reducing DHT and slowing follicle miniaturisation. Peptides like GHK-Cu operate through gene expression modulation, follicle proliferation, and tissue remodelling pathways. TB-500 and BPC-157 work through angiogenic and anti-inflammatory mechanisms. These are complementary biological approaches rather than direct alternatives, and none of the peptides discussed here have accumulated the decades of clinical evidence that minoxidil has built through approved use.